Berlin MDCC

Main Menu

  • Home
  • International Banking Facility
  • Vega
  • High Dimension
  • Yield to Worst
  • Debt

Berlin MDCC

Header Banner

Berlin MDCC

  • Home
  • International Banking Facility
  • Vega
  • High Dimension
  • Yield to Worst
  • Debt
High Dimension
Home›High Dimension›Cell and gene therapy research has weathered the storm of COVID-19, leaving a bright future ahead of it

Cell and gene therapy research has weathered the storm of COVID-19, leaving a bright future ahead of it

By Sandra D. Adler
May 13, 2022
0
0

Pharmacy hours interviewed Aklilu Tedla, Vice President of Strategy and Business Development at Cardinal Health, to discuss the future of pharmacies as more cell and gene therapy products become available to patients.

Question: What cell and gene therapies are being developed that may be approved in the near future?

Aklilu Tedla: I think this is one of the times when the FDA has a lot of cell and gene therapies on the docket for approval, and we expect that to accelerate over the next few years. Just to give 2 examples, there is BioMarin’s hemophilia A gene therapy, which is promising; bluebird bio offers a few new therapies, one for beta thalassemia and another for very rare brain disorders. So a number of products that are coming – these are just 2 examples.

Question: What impact could these upcoming approvals have on the industry?

Aklilu Tedla: So let’s start with the patient’s point of view. I mean, you’re going to have patients who have results that they probably couldn’t have expected years ago. So the quality of life, the outcomes for the patients – but just think of the dimension of the caregivers – so a huge impact on their families.

I think once you start stepping back and looking at the disruption in healthcare, I think there’s going to be a lot going on. These products, just going back to tolerance therapies – out of my body, back into my body sounds very simple, but there’s a lot of chain of custody, chain of identity that you have to establish to make sure the Product integrity is maintained throughout. There has to be long-term safety oversight, things that we don’t do today. I think we will have to innovate in cold storage and cryoshipping, for example.

So look at the impact, not just in terms of the patient, but also all service providers in the field need to rethink the value they bring to these types of businesses.

Question: What is your vision for the future of the cell and gene therapy space?

Aklilu Tedla: Bright. I would say this market is about to explode. It’s not without risk – it’s high risk, high reward. The industry has, in some cases, weathered the storm of COVID-19 and the delays, and now we’re starting to see a lot of traction. So I think the future of this industry is great.

Related posts:

  1. Nano Dimension already 6% up, virtually 4 hours earlier than the market opens
  2. Badminton Footwear Beneath Rs 3,000: Prime Picks On-line | Most Needed Merchandise
  3. Followers should not insist on the offense
  4. 25 free brokers linked to Joe Decide, Dave Gettleman and Giants coaches | Curtis Samuel, Ryan Fitzpatrick, Jason McCourty, extra

Categories

  • Debt
  • High Dimension
  • International Banking Facility
  • Vega
  • Yield to Worst

Recent Posts

  • Run-off, primary elections in Alabama, Georgia, Virginia, Arkansas and DC: LIVE UPDATES
  • Germany risks recession as Russian gas crisis deepens
  • Historical victory of Gustavo Petro in the elections in Colombia
  • Lime Oil Market Size 2022-2029
  • SAMPLES: Revolution x Coca Cola Eyeshadow Palette
  • Privacy Policy
  • Terms and Conditions